12 Month Price Forecast For PEN
Distance to PEN Price Forecasts
PEN Price Momentum
๐ค Considering Penumbra (PEN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 5:30 AM UTC
PEN Analyst Ratings & Price Targets
Based on our analysis of 19 Wall Street analysts, PEN has a consensus that is bullish. The median price target is $266.00, with forecasts ranging from $230.00 to $323.00. Currently, there are 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
With PEN currently trading at $265.94, the median price forecast suggests a 0.0% upside. The most optimistic forecast comes from Jason Mills at Canaccord Genuity, projecting a 21.5% upside, while Richard Newitter at Truist Securities provides the most conservative target, suggesting a -13.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PEN Analyst Consensus
PEN Price Target Range
Latest PEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PEN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 23, 2025 | Baird | David Rescott | Outperform | Maintains | $305.00 |
Jan 21, 2025 | UBS | Priya Sachdeva | Buy | Initiates | $305.00 |
Dec 18, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $285.00 |
Dec 17, 2024 | Oppenheimer | Steve Lichtman | Outperform | Initiates | $275.00 |
Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Upgrade | $275.00 |
Dec 11, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $245.00 |
Dec 9, 2024 | Canaccord Genuity | Jason Mills | Buy | Maintains | $323.00 |
Dec 2, 2024 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
Nov 26, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $270.00 |
Nov 20, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $250.00 |
Nov 4, 2024 | Canaccord Genuity | Buy | Maintains | $0.00 | |
Oct 31, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $235.00 |
Oct 31, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Oct 31, 2024 | Baird | David Rescott | Outperform | Maintains | $248.00 |
Oct 31, 2024 | BTIG | Buy | Maintains | $0.00 | |
Oct 25, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
Oct 18, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $225.00 |
Oct 16, 2024 | Canaccord Genuity | Jason Mills | Buy | Maintains | $235.00 |
Oct 15, 2024 | Baird | Outperform | Maintains | $0.00 | |
Oct 14, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $234.00 |
Stocks Similar to Penumbra Inc
The following stocks are similar to Penumbra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Penumbra Inc (PEN) Financial Data
Penumbra Inc has a market capitalization of $10.06B with a P/E ratio of 301.3x. The company generates $1.16B in trailing twelve-month revenue with a 3.0% profit margin.
Revenue growth is +11.1% quarter-over-quarter, while maintaining an operating margin of +11.7% and return on equity of +3.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Penumbra Inc (PEN) Company Overview
About Penumbra Inc
Develops and markets medical devices globally.
The company generates revenue by designing, manufacturing, and selling a wide range of medical devices, primarily used for vascular interventions and neurovascular treatments. Its products include thrombectomy systems, access devices, and embolization solutions, which are sold through direct sales and distribution channels in both domestic and international markets.
Founded in 2004 and headquartered in Alameda, California, Penumbra, Inc. focuses on innovation in medical technology. The companyโs product portfolio addresses critical medical needs in peripheral and neurovascular applications, positioning it well within the growing healthcare sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
4,200
CEO
Mr. Adam Elsesser J.D.
Country
United States
IPO Year
2015
Website
www.penumbrainc.comPenumbra Inc (PEN) Latest News & Analysis
Penumbra, Inc. (NYSE: PEN) will hold a conference call on February 18, 2025, at 4:30 PM ET to discuss its Q4 and full year 2024 financial results.
Penumbra's upcoming earnings call may impact stock performance, providing insights into financial health and growth prospects that influence investor sentiment and decision-making.
Penumbra (PEN) shows above-average growth in financials, indicating a strong market position and potential for outperformance.
Penumbra's above-average financial growth suggests strong future performance, potentially leading to increased stock value and attracting more investment interest.
Consider investing in YPF, TEF, PEN, DECK, and ANF to capitalize on their increased efficiency levels.
Higher efficiency levels in companies like YPF, TEF, PEN, DECK, and ANF can lead to improved profitability, making them attractive investment opportunities for potential growth.
Investors are advised to focus on low-beta stocks to manage market volatility, with AVO, TXO, PEN, and STRA identified as strong options.
Low-beta stocks like AVO, TXO, PEN, and STRA can provide stability and potential gains during market volatility, appealing to risk-averse investors seeking to preserve capital.
PEN is attracting investor attention due to its robust Thrombectomy business and strategic plans for international expansion.
PEN's robust Thrombectomy segment and expansion into international markets signal potential revenue growth, making it an attractive opportunity for investors seeking strong performance.
Penumbra (PEN) shares surged recently, with above-average trading volume, but earnings estimate revisions may not lead to further price increases soon.
Penumbra's share surge and high trading volume indicate strong investor interest, but revised earnings estimates may signal potential volatility or a plateau in price growth.
Frequently Asked Questions About PEN Stock
What is Penumbra Inc's (PEN) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Penumbra Inc (PEN) has a median price target of $266.00. The highest price target is $323.00 and the lowest is $230.00.
Is PEN stock a good investment in 2025?
According to current analyst ratings, PEN has 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $265.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for PEN stock?
Wall Street analysts predict PEN stock could reach $266.00 in the next 12 months. This represents a 0.0% increase from the current price of $265.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Penumbra Inc's business model?
The company generates revenue by designing, manufacturing, and selling a wide range of medical devices, primarily used for vascular interventions and neurovascular treatments. Its products include thrombectomy systems, access devices, and embolization solutions, which are sold through direct sales and distribution channels in both domestic and international markets.
What is the highest forecasted price for PEN Penumbra Inc?
The highest price target for PEN is $323.00 from Jason Mills at Canaccord Genuity, which represents a 21.5% increase from the current price of $265.94.
What is the lowest forecasted price for PEN Penumbra Inc?
The lowest price target for PEN is $230.00 from Richard Newitter at Truist Securities, which represents a -13.5% decrease from the current price of $265.94.
What is the overall PEN consensus from analysts for Penumbra Inc?
The overall analyst consensus for PEN is bullish. Out of 19 Wall Street analysts, 14 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $266.00.
How accurate are PEN stock price projections?
Stock price projections, including those for Penumbra Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.